Effectiveness and Immunogenicity of mRNA vaccines COVID-19 among healthcare workers and Nursing home residents

Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 Abstract Severe acute respiratory syndrome coronavirus 2 is the beta-coronavirus responsible for the infection called coronavirus disease 2019 (COVID-19). This disease is a major global health issue due to globally high rates of mortality and morbidity. PfizerBioNTech and Moderna are the two recently approved mRNA vaccination against COVD-19 infection, and priority groups for vaccination against COVID-19 infection is healthcare workers and nursing home residents. The mRNA vaccination programmes for healthcare workers and nursing home residents are an essential strategy for protecting them from new cases of SARS-CoV-2 infection and for providing a much safer clinical environment. This research reviewed several studies regarding the effectiveness and immunogenicity of mRNA vaccines among healthcare professionals and nursing home residents in healthcare settings.This study has shown that the effectiveness and efficacy of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines after the second dose in HCWs and NHR is highly effective for preventing against asymptomatic and symptomatic COVID-19 due to infection with wild-type variants in healthcare settings. A single dose of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines led to high immunogenicity in the majority of HCWs and NHRs 21 days post vaccination. One of the more significant findings to emerge from this study is that significant differences in immunogenicity by gender, age, obesity, smoking habits, health status, fever and infection status. The aim of this research is to evaluate the effectiveness and efficiency of a primary and a booster mRNA vaccination COVID-19 (PfizerBioNTech/Moderna) in healthcare staff and nursing home residents for reducing symptomatic and asymptomatic of SARS-CoV-2 infection. It will also evaluate the immunogenicity of mRNA COVID-19 vaccines for inducing humoral and cellular immune responses among vaccinated naïve infections and prior infections of COVID-19 compared with unvaccinated healthcare providers and nursing home residents.

the beta-coronavirus responsible for the infection called coronavirus disease 2019 (COVID-19). This disease is a major global health issue due to globally high rates of mortality and morbidity. PfizerBioNTech and Moderna are the two recently approved mRNA vaccination against COVD-19 infection, and priority groups for vaccination against COVID-19 infection is healthcare workers and nursing home residents. The mRNA vaccination programmes for healthcare workers and nursing home residents are an essential strategy for protecting them from new cases of SARS-CoV-2 infection and for providing a much safer clinical environment. This research reviewed several studies regarding the effectiveness and immunogenicity of mRNA vaccines among healthcare professionals and nursing home residents in healthcare settings.This study has shown that the effectiveness and efficacy of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines after the second dose in HCWs and NHR is highly effective for preventing against asymptomatic and symptomatic COVID-19 due to infection with wild-type variants in healthcare settings. A single dose of the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines led to high immunogenicity in the majority of HCWs and NHRs 21 days post vaccination. One of the more significant findings to emerge from this study is that significant differences in immunogenicity by gender, age, obesity, smoking habits, health status, fever and infection status. The aim of this research is to evaluate the effectiveness and efficiency of a primary and a booster mRNA vaccination COVID-19 (PfizerBioNTech/Moderna) in healthcare staff and nursing home residents for reducing symptomatic and asymptomatic of SARS-CoV-2 infection. It will also evaluate the immunogenicity of mRNA COVI